Clinical Trials Directory

Trials / Completed

CompletedNCT02891694

Metalloproteinases and Recurrent Corneal Erosion Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
19 (actual)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane. The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Conditions

Interventions

TypeNameDescription
OTHERin vitro immuno-histo-chemical analysis of corneal epithelium

Timeline

Start date
2016-12-02
Primary completion
2020-06-26
Completion
2020-11-26
First posted
2016-09-07
Last updated
2020-12-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02891694. Inclusion in this directory is not an endorsement.

Metalloproteinases and Recurrent Corneal Erosion Syndrome (NCT02891694) · Clinical Trials Directory